Giving antibiotics to animals, primarily livestock raised for food, has wide-ranging effects that extend well beyond the animals themselves. While antibiotics help prevent disease and historically boosted growth rates in farm animals, they also drive the development of antibiotic-resistant bacteria that can spread to humans through food, water, and the environment. Roughly 110,000 tons of antibiotics were used in global livestock production in 2019, and that number could climb to over 143,000 tons by 2040 without significant policy changes.
Why Animals Receive Antibiotics
Antibiotics are given to farm animals for three main purposes: treating sick animals, preventing disease in healthy ones, and, historically, accelerating growth. Treatment works the same way it does in humans: a sick animal gets a course of antibiotics to clear an infection. Prevention and group-level treatment are where animal medicine diverges sharply from human medicine.
Preventive dosing means giving antibiotics to healthy animals based on perceived risk factors like overcrowding, transport stress, weaning, diet changes, or a history of outbreaks in the herd. When disease has already appeared in a group, the remaining healthy animals often receive antibiotics too, a practice called metaphylaxis. The threshold is typically when illness rates exceed 10% of the group for two to three consecutive days. In both cases, healthy animals are receiving drugs to head off infections that haven’t occurred yet.
Growth promotion, the most controversial use, involved feeding animals low (subtherapeutic) doses of antibiotics continuously to make them gain weight faster on less feed. This practice was banned in the European Union in 2006. In the United States, the FDA completed a phase-out in January 2017, making it illegal to use medically important antibiotics for growth promotion. All 31 drug applications that included growth-promotion claims had their production-use indications withdrawn, and any remaining therapeutic uses in feed now require authorization from a licensed veterinarian.
How Low-Dose Antibiotics Affect Animal Biology
The growth-promoting effect of antibiotics puzzled scientists for decades. Recent research points to changes in gut bacteria and cellular energy production as the likely explanation. At subtherapeutic doses, antibiotics reshape the microbial community in an animal’s digestive tract rather than simply killing bacteria off. Studies in broiler chickens found that common growth-promoting antibiotics consistently increased bacteria that produce butyrate and lactic acid, both of which help animals extract more energy from their feed. At the same time, these drugs reduced bacteria that break down bile salts, which likely improved fat absorption.
The net result is that animals harvest more calories and nutrients from the same amount of food. At the cellular level, low-dose antibiotics may trigger a stress-adaptation response in mitochondria, the energy-producing structures inside cells, prompting them to work more efficiently. Each antibiotic reshapes the gut differently. Some shift dozens of bacterial populations while others have minimal visible effect, but the overall pattern of enhanced energy harvest from feed appears consistent across different drugs.
One concerning finding: all growth-promoting antibiotics studied enriched populations of Escherichia/Shigella bacteria in the gut, a group that includes strains capable of causing disease. This enrichment of potentially harmful bacteria, even while the animal appears healthy and grows faster, hints at the hidden costs of routine antibiotic use.
The Antibiotic Resistance Problem
The most significant consequence of giving antibiotics to animals is the acceleration of antibiotic resistance, a problem that directly threatens human medicine. When bacteria in an animal’s gut are exposed to antibiotics repeatedly, resistant strains survive and multiply. These resistant bacteria then travel to humans through several routes.
The most direct pathway is through food. Resistant bacteria present on meat at the point of slaughter can survive processing and reach consumers. Pork and poultry are both documented sources of drug-resistant Salmonella strains that infect humans. One study estimated that roughly 1.5% of chicken meals expose the consumer to a meaningful dose of E. coli resistant to cephalosporins, a critical class of antibiotics used in human medicine.
Food isn’t the only route. Resistant bacteria also spread through cross-contamination during food processing, when resistant organisms from raw animal products transfer to other foods or kitchen surfaces. And resistance genes themselves can jump between bacterial species, meaning a harmless bacterium carrying resistance genes picked up on a farm could transfer those genes to a dangerous pathogen inside a human gut.
Environmental Contamination
Animals excrete between 30% and 90% of administered antibiotics in their urine and feces, largely unmetabolized. Manure used as fertilizer can contain up to 90% of these unmetabolized drugs, which then enter soil and water systems. This creates a persistent environmental reservoir where bacteria encounter antibiotics at concentrations high enough to drive resistance but too low to kill effectively.
Different antibiotic classes persist in the environment for different lengths of time. Macrolide antibiotics, for instance, have a soil half-life ranging from 5 to 120 days. Fluoroquinolones are chemically and thermally stable, binding rapidly to soil particles where they can persist for much longer. These residues don’t just sit in farm fields. They leach into groundwater, run off into streams, and create conditions where resistant bacteria thrive far from the farm where the antibiotics were originally used.
The result is a cycle: antibiotics given to animals produce resistant bacteria and chemical residues that enter the environment, where they promote further resistance development in wild bacterial populations that may eventually circle back to infect both animals and humans.
The Scale of Global Use
Asia and the Pacific region dominates global livestock antibiotic use, accounting for roughly 65% of all consumption. South America follows at about 19%, with Africa at 5.7% and North America at 5.5%. Under current trends, global use is projected to reach approximately 143,500 tons by 2040, a nearly 30% increase from 2019 levels driven primarily by expanding livestock production in developing regions.
That growth isn’t inevitable. Modeling suggests that changes in both livestock numbers and antibiotic use intensity could cut projected 2040 usage by as much as 57% compared to the business-as-usual scenario. The European ban on growth promoters demonstrated that major reductions are possible without collapsing the livestock industry, though the transition required investment in alternative disease prevention strategies.
Alternatives Gaining Ground
As regulations tighten around antibiotic use, researchers are testing replacements. Bacteriophages, viruses that specifically target bacteria, have shown striking results in controlled studies. Phage cocktails reduced Staphylococcus aureus (including MRSA strains) in cattle by 64% to 95%. In swine, phage therapy achieved 100% elimination of Salmonella from tonsil tissue within six hours and 99% to 100% reduction of Salmonella in intestinal tissue within 48 hours.
Chickens have also responded well. Phage-treated chickens carried Campylobacter counts more than 3 log levels lower (over 1,000 times fewer bacteria) than untreated birds through to slaughter. In flocks exposed to Salmonella Gallinarum, phage treatment as a feed additive reduced mortality from 30% to just 5%. Combinations of phages with probiotics eliminated diarrhea in calves within 24 to 48 hours.
These alternatives target specific pathogens without disrupting the broader gut microbiome or promoting resistance in unrelated bacteria. They’re not yet used at the same industrial scale as antibiotics, and consistent real-world performance across different farm conditions remains an active area of work. But the lab and field trial results suggest they could substantially reduce agriculture’s dependence on antibiotics while still keeping animals healthy.
The Economic Tension
From a farm economics perspective, antibiotics have functioned as both a production booster and a cheap insurance policy against disease losses in crowded conditions. Removing them means farmers face higher costs from improved housing, better ventilation, reduced stocking densities, or purchasing alternative treatments. These costs are real and immediate, while the benefits of reduced resistance are diffuse and long-term.
Economists describe antibiotic use in livestock as a negative externality: the farm captures the economic benefits while the costs of resistance are spread across the entire healthcare system and general population. The total economic value of antibiotics in animal production, when accounting for the downstream losses from resistance, is significantly lower than what the farm-level economics suggest. This gap between private benefit and public cost is the core reason regulatory intervention has been necessary to drive change.